Evidence map›Paper›PMID 38205214›Full record

ArticleTranslational lung cancer research2023

Cathepsin detection to identify malignant cells during robotic pulmonary resection.

Patrick Bou-Samra, Austin Chang, Emily Guo, Feredun Azari, Gregory Kennedy, John T Santini, Eric S Bensen, Doraid Jarrar, Sunil Singhal

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Patrick Bou-SamraDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
Austin ChangDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
Emily GuoDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
Feredun AzariDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
Gregory KennedyDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
John T SantiniVergent Bioscience, Minneapolis, MN, USA.
Eric S BensenVergent Bioscience, Minneapolis, MN, USA.
Doraid JarrarDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
Sunil SinghalDepartment of Surgery, The University of Pennsylvania Perelman School of Medicine, Pennsylvania, PA, USA.
University of Pennsylvania · US

Funding

TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8M
Improving lung cancer surgery with an intraoperative, tumor-targeted, activatable fluorescent imaging agentR44CA277890 · NCI · VERGENT BIOSCIENCE, INC. · PI BENSEN, ERIC SCOTT, SINGHAL, SUNIL · 2022 to 2023
$2.0M
NCI NIH HHS P01 CA087971NCI NIH HHS R44 CA277890
6 · The paper itself

Abstract

Background: Intraoperative molecular imaging (IMI) uses a fluorescent probe to identify occult cancers. VGT-309 is a quenched activity-based probe that is activated in the presence of cathepsins, enzymes overexpressed in cancer cells, and detected by near-infrared (NIR) light. This study aims to evaluate the sensitivity and the positive predictive value (PPV) of robotic-assisted thoracic surgery (RATS) with intraoperative molecular imaging (RIMI) using VGT-309 to localize tumors using NIR light to detect areas with increased cathepsin activity. Our secondary outcome was to compare RIMI to video-assisted thoracic surgery (VATS) with intraoperative molecular imaging (VIMI). Methods: In a phase 2 clinical trial at the University of Pennsylvania, patients (n=10) with suspicious pulmonary lesions underwent RATS. First, white light was used followed by RIMI to identify tissues with increased cathepsin activity. Then, VIMI was performed to compare the sensitivity and PPV in identifying the cathepsin activity. The resected specimens were then evaluated for fluorescence and underwent histopathological analysis for cathepsin expression. Image analysis was performed using ImageJ software. Statistical analysis was conducted using IBM SPSS Statistics software. A P value of 0.05 or less was considered significant. Results: RATS with white light identified 6 out of the 10 pulmonary nodules, whereas adding RIMI identified an additional 4 more pulmonary nodules. RIMI and VIMI were able to detect the same 8/10 (80%) nodules. The addition of VIMI did not identify any lesions that RIMI may have missed. The mean fluorescence intensity of tumors visualized by RIMI was 115.81 A.U. [standard deviation (SD) =58.57] compared to 95.6 A.U. (SD =14.81) by VIMI (P=0.41). The mean tumor-to-background ratios (TBR) of tumors visualized by RIMI was 9.20 (SD =9.12) compared to 2.29 A.U. (SD =1.11) using VIMI (P=0.1). The sensitivity of RIMI and VIMI was 88.9% which was superior to that of RATS (55.6%). The PPV of RATS was 83.3% compared to 100% in RIMI and VIMI. Conclusions: RIMI is a valuable option for visualization of occult disease using VGT-309-guided IMI through identifying areas of increased cathepsin activity. In this small series, RIMI and VIMI showed clinical equivalence in sensitivity and PPV of detecting cathepsin activity.

Indexed as

cathepsinintraoperative molecular imaging (IMI)Robotic-assisted thoracic surgery (RATS)

Identifiers

PMID38205214
PMCPMC10775009
OpenAlexW4390238029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.